Singhi A N, Lee T-G, Ahn H-M, Shin H-R, Choi M J, Jo M H, Oh H-K, Kim D-W, Kang S-B
Department of Surgery, Seoul National University Bundang Hospital, 173 Gumi-ro, Bundang-gu, Seongnam, 13620, Republic of Korea.
Department of General Surgery, Saifee Hospital, Mumbai, Maharashtra, India.
Tech Coloproctol. 2024 Dec 11;29(1):15. doi: 10.1007/s10151-024-03046-7.
Non-radical management is an option for good responders to neoadjuvant chemoradiotherapy in mid-to-low rectal cancer. This study aimed to analyze risk factors for lymph node metastasis in patients with ypT2 rectal cancer, exploring the possibility of non-radical management.
We included patients with ypT2 rectal cancer who received neoadjuvant chemoradiotherapy followed by total mesorectal excision between January 2004 and December 2022. Clinicopathological parameters were evaluated to identify risk factors for lymph node metastasis.
Among the 198 patients, 158 (79.8%) had ypT2N0 and 40 (20.2%) had ypT2N+. In univariable analyses, the risk factors of lymph node metastasis were perineural invasion (48.0% vs. 16.3% without perineural invasion, P < 0.001), female sex (30.0% vs. 14.8% with male sex, P = 0.011), and clinically positive nodes after neoadjuvant chemoradiotherapy (32.6% vs. 16.4% with negative nodes, P = 0.017). These factors were confirmed as independent risk factors in multivariable analyses: perineural invasion (odds ratio [OR]: 4.50; 95% confidence interval [CI]: 1.79-11.29; P < 0.001), female sex (OR: 2.62; 95% CI: 1.24-5.52; P = 0.012) and clinical node involvement after neoadjuvant chemoradiotherapy (OR: 2.28; 95% CI: 1.03-5.05; P = 0.012). The rate of lymph node metastasis in patients with ypT2 rectal cancer without any of these three risk factors was 12.5%.
This study revealed a high probability of lymph node metastasis in patients with ypT2 rectal cancer, even in the absence of identifiable risk factors. We confirm that lymph node metastasis should be considered in ypT2 rectal cancer.
对于中低位直肠癌新辅助放化疗疗效良好的患者,非根治性治疗是一种选择。本研究旨在分析ypT2期直肠癌患者淋巴结转移的危险因素,探讨非根治性治疗的可能性。
我们纳入了2004年1月至2022年12月期间接受新辅助放化疗后行全直肠系膜切除术的ypT2期直肠癌患者。评估临床病理参数以确定淋巴结转移的危险因素。
198例患者中,158例(79.8%)为ypT2N0,40例(20.2%)为ypT2N+。在单因素分析中,淋巴结转移的危险因素为神经侵犯(神经侵犯组为48.0%,无神经侵犯组为16.3%,P<0.001)、女性(女性组为30.0%,男性组为14.8%,P = 0.011)以及新辅助放化疗后临床淋巴结阳性(淋巴结阳性组为32.6%,淋巴结阴性组为16.4%,P = 0.017)。在多因素分析中,这些因素被确认为独立危险因素:神经侵犯(比值比[OR]:4.50;95%置信区间[CI]:1.79 - 11.29;P<0.001)、女性(OR:2.62;95% CI:1.24 - 5.52;P = 0.012)以及新辅助放化疗后临床淋巴结受累(OR:2.28;95% CI:1.03 - 5.05;P = 0.012)。无这三个危险因素的ypT2期直肠癌患者淋巴结转移率为12.5%。
本研究表明,即使没有可识别的危险因素,ypT2期直肠癌患者也有较高的淋巴结转移概率。我们证实ypT2期直肠癌应考虑淋巴结转移情况。